OverviewSuggest Edit

Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes.

The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. BTI-320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine. IPOXYN is a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. OXYFEX can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.

TypePublic
Founded2009
HQLawrence, US
Websitebostonti.com

Latest Updates

Employees (est.) (Dec 2018)1(-50%)
Revenue (FY, 2019)$16.3 K(-48%)
Share Price (Oct 2020)$0 (+5%)
Cybersecurity ratingAMore

Key People/Management at Boston Therapeutics

Conroy Chi-Heng Cheng

Conroy Chi-Heng Cheng

Interim Chief Executive Officer, Interim Chief Financial Officer, and Director
Stephen Spanos

Stephen Spanos

Chief Financial Officer
Show more

Boston Therapeutics Office Locations

Boston Therapeutics has offices in Lawrence and Hackensack
Lawrence, US (HQ)
354 Merrimack St #4
Hackensack, US
433 Hackensack Ave Level L
Show all (3)

Boston Therapeutics Financials and Metrics

Boston Therapeutics Revenue

Boston Therapeutics's revenue was reported to be $16.33 k in FY, 2019
USD

Revenue (FY, 2019)

16.3k

Net income (FY, 2019)

(3.7m)

EBIT (FY, 2019)

(3.9m)

Market capitalization (14-Oct-2020)

1.2m

Closing stock price (14-Oct-2020)

0.0

Cash (31-Dec-2019)

6.7k

EV

5.2m
Boston Therapeutics's current market capitalization is $1.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.1k42.3k323.4k199.6k98.9k98.9k29.4k31.7k16.3k

Revenue growth, %

0%

Cost of goods sold

6.4k56.9k278.2k175.8k240.5k94.1k

Gross profit

(2.3k)(14.6k)45.2k23.8k(141.5k)4.7k
USDQ2, 2011

Financial Leverage

1.6 x
Show all financial metrics

Boston Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Boston Therapeutics Online and Social Media Presence

Embed Graph

Boston Therapeutics News and Updates

Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia

LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches the initial sales and marketing of cross border produc…

Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia

LAWRENCE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches an initial sale of product in Myanmar and test marke…

Boston Therapeutics to launch social commerce channel for Sugardown® in China

For product distribution via a multi-purpose super-app that fuses communications with commerce For product distribution via a multi-purpose super-app that fuses communications with commerce

Boston Therapeutics Frequently Asked Questions

  • When was Boston Therapeutics founded?

    Boston Therapeutics was founded in 2009.

  • Who are Boston Therapeutics key executives?

    Boston Therapeutics's key executives are Conroy Chi-Heng Cheng and Stephen Spanos.

  • How many employees does Boston Therapeutics have?

    Boston Therapeutics has 1 employees.

  • What is Boston Therapeutics revenue?

    Latest Boston Therapeutics annual revenue is $16.3 k.

  • What is Boston Therapeutics revenue per employee?

    Latest Boston Therapeutics revenue per employee is $16.3 k.

  • Who are Boston Therapeutics competitors?

    Competitors of Boston Therapeutics include Laboratorios Farmaceuticos ROVI, Barsian Darou and GSK.

  • Where is Boston Therapeutics headquarters?

    Boston Therapeutics headquarters is located at 354 Merrimack St #4, Lawrence.

  • Where are Boston Therapeutics offices?

    Boston Therapeutics has offices in Lawrence and Hackensack.

  • How many offices does Boston Therapeutics have?

    Boston Therapeutics has 3 offices.